Invivo Partners joins Sofinnova Partners in Signadori Bio

Signadori Bio, a biotechnology company created by Sofinnova Partners and Gustave Roussy , is developing a revolutionary cell therapy platform for oncology.

Barcelona, ​​Spain, [8/4/2025] – Invivo Partners announced today its investment in Signadori Bio, a pioneering biotechnology company founded through a collaboration between Sofinnova Partners, Gustave Roussy, and scientific founders Dr. Jean-Luc Perfettini and Prof. Nathalie Chaput.

Signadori Bio is a preclinical-stage biopharmaceutical company developing an innovative cell therapy platform to transform cancer treatment. Its proprietary platform originates from Gustave Roussy, a world-renowned cancer center.

This initiative is supported by Sofinnova's €165 million biotech acceleration fund, Biovelocita II, which focuses on driving disruptive science in Europe.
"Taking cell therapies from discovery to patients requires deep expertise, strategic guidance, and the right ecosystem. Invivo Partners' strong track record in cell therapy will be key to accelerating the company's growth and bringing innovative treatments to the clinic," commented Matthieu Coutet, CEO of Signadori Bio and partner at Sofinnova Partners.

This strategic investment underscores Invivo's commitment to developing next-generation cell therapies in oncology and reinforces its role as a key investor in early-stage biotechnology innovation. Together with Sofinnova Partners, a recognized leader in life sciences investment, Invivo is actively shaping the future of advanced therapies by supporting transformative science from inception to impact.

“It is an honor to join Sofinnova Partners in this bold initiative. The science emerging from Gustave Roussy exemplifies the type of innovation Invivo Partners was created to support: disruptive, data-driven, and deeply rooted in clinical needs. We are thrilled to support this new chapter of oncology innovation.”
— Laura Rodríguez, Partner at Invivo Partners.

About Invivo Partners

Invivo Partners is a venture capital firm specializing in early-stage life sciences companies. It is managed by Luis Pareras, Albert Ferrer, and Laura Rodríguez, with investments in 16 companies and three funds under management.
It recently announced its third fund, targeting €100 million for investments in early-stage life sciences companies working in advanced therapies, synthetic biology, and artificial intelligence. Invivo Ventures III is predominantly funded by private investors, with support from institutional entities such as the European Investment Fund (EIF), Fond-ICO Next Tech, the Catalan Institute of Finance, and Barcelona City Council.

More information: https://invivo.partners

About Sofinnova Partners

Sofinnova Partners is a leading European life sciences venture capital firm specializing in healthcare and sustainability. Based in Paris, London, and Milan, the team combines scientific, medical, and business expertise.
It is actively focused on building companies across the entire life sciences investment value chain, from seed to later stages.

Founded in 1972, Sofinnova has 50 years of experience supporting more than 500 companies and creating global market leaders. It currently manages over €4 billion in assets.
More information: sofinnovapartners.com

About Gustave Roussy

Ranked by Newsweek magazine as the leading cancer center in Europe and fourth in the world, Gustave Roussy is a referral center dedicated exclusively to cancer patients. It is a founding member of the Paris-Saclay Cancer Cluster and a source of diagnostic and therapeutic advances.

It treats nearly 50,000 patients a year, including 3,500 children and adolescents. Its approach integrates research, patient care, and teaching. It specializes in rare cancers and complex tumors, offering personalized treatments that combine advanced medical techniques with care focused on the human aspect of the patient.

With offices in Villejuif and Chevilly-Larue, it has 4,100 professionals. Forty percent of its patients participate in clinical trials.
More information: www.gustaveroussy.fr/en

About Gustave Roussy Transfer

Founded in 2000, it is the technology transfer subsidiary of Gustave Roussy. Its missions are (1) to create and identify innovations generated by Gustave Roussy's research teams, (2) to establish and oversee translational collaborations, and (3) to support and promote the institute's entrepreneurial projects.